Central Nervous System (CNS)
Worldwide Clinical Trials was retained to intervene in a Phase IIb, multinational, randomized, double-blind, placebo-controlled study in subjects with progressive cognitive decline compatible with the diagnosis of prodromal Alzheimer’s disease (AD) and we’ve provided a working and significant outcome.
Exaggerated and highly variable placebo response remains one of the principal challenges in the development of drugs for major depressive disorder (MDD). The following review summarizes some of the more salient strategies designed to minimize placebo response in MDD trials.
Central Nervous System (CNS), Clinical Research, Multiple Sclerosis, Neuroscience
Jackie Brusch, Senior Manager, Global Content Marketing, sits down with Carla Lema Tome, Therapeutic Strategy Lead, CNS, to get an exclusive sneak peek of the on-demand webinar, “Moving the Needle Forward on MS Research.”
An Evaluation of Independent Subject Eligibility Reviews to Ensure Enrollment of High Quality Appropriate Subjects in Mild Alzheimer’s Disease (AD) Trials
Central Nervous System (CNS), Neuroscience
See the details of the use of Naltrexone to Block Opioid Side Effects in Healthy Volunteers: Effects of Dose and Food in this poster.